China Levies Zero Tariff on Active Pharmaceutical Ingredients of COVID-19, Cancer, and Rare Disease Drugs

by Grace Wang Jan 05, 2023

According to China’s 2023 Tariff Adjustment Plan, 1,020 categories of products can enjoy interim import tariffs that are lower than most-favored-nation (MFN) tariffs from Jan. 1, 2023. 

Among the 1,020 categories of products, 22 are active pharmaceutical ingredients (APIs) of medicines for treating COVID-19, cancer, and rare diseases. Their provisional tariff rates are all cut to 0%.1

Tax Code

Product

2023 MFN Tariff Rate %

2023 Interim Tariff Rate%

29337900

API of COVID-19 drug

Nirmatrelvir

9

0

29309090

APIs of rare disease / orphan drugs

Penicillamine

6.5

0

29337900

Pirfenidone

9

0

29342000

Riluzole

6.5

0

29359000

Bosentan

6.5

0

28439000

APIs of anti-cancer drugs

Oxaliplatin;

Carboplatin;

Nedaplatin;

Cisplatin

5.5

0

29225090

Mitoxantrone Hydrochloride

6.5

0

29242990

Flutamide

6.5

0

29309090

Bicalutamide

6.5

0

29329990

Docetaxel;

Paclitaxel

6.5

0

29334900

Pyrotinib Maleate

6.5

0

29335990

Imatinib Mesylate;

Azathioprine;

Pemetrexed Disodium;

Calcium Levofolinate;

Flumatinib Mesylate;

Almonertinib Mesilate;

Zanubrutinib

6.5

0

29336990

Oteracil Potassium

6.5

0

29337900

Lenalidomide

9

0

29339900

Anastrozole;

Letrozole;

Bortezomib;

Temozolomide

6.5

0

29341090

Dasatinib

6.5

0

29349990

Decitabine;

Floxuridine; Cyclophosphamide;

Gefitinib;

Capecitabine;

Raltitrexed;

Fludarabine Phosphate;

Tegafur;

Cytarabine;

Cytarabine Hydrochloride;

Icotinib Hydrocholride; Gemcitabine Hydrochloride;

Ifosfamide;

Fruquintinib

6.5

0

29371900

Triptorelin Acetate

4

0

29372319

Formestane

4

0

29372900

Exemestane

4

0

29397990

Vinorelbine Tartrate;

Vincristine Sulfate;

Topotecan Hydrochloride;

Irinotecan Hydrochloride

4

0

29419090

Pirarubicin;

Mitomycin;

Epirubicin Hydrochloride;

Doxorubicin Hydrochloride; Bleomycin A5 Hydrochloride;

Daunorubicin Hydrochloride;
Idarubicin Hydrochloride

6

0

Since 2018, China has exempted the tariffs on APIs of the 1st and 2nd lists of anti-cancer and rare disease drugs, indicating the further opening of the Chinese pharma market.

Related: China Cuts VAT to 3% for the 3rd List of Anti-cancer and Rare Disease Drugs

Grace Wang
ChemLinked Regulatory Analyst / Editor
+ FOLLOW
Copyright: unless otherwise stated all contents of this website are ©2023 - REACH24H Consulting Group - All Rights Reserved - For permission to use any content on this site, please contact cleditor@chemlinked.com